NCT03952923 - CD19-CAR-T in B-cell Malignancies Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

January 1, 2021

Study Completion Date

March 31, 2021

Conditions

B-cell Malignancy

Interventions

BIOLOGICAL

CD19-CAR-T cells

CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.

Trial Locations (1)

065200

Hebei Yanda Ludaopei Hospital, Sanhe